MIR6795: A Potential Drug Target and Biomarker for Heart Disease

MIR6795: A Potential Drug Target and Biomarker for Heart Disease

Heart disease is a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems and quality of life. The condition is characterized by a range of cardiovascular risk factors, including blood pressure, cholesterol, blood sugar levels, smoking, and family history, which increase the likelihood of developing heart disease. While several medications have been developed to treat heart disease, there is still a need for new and more effective treatments.

One potential drug target for heart disease is MIR6795, a protein that is expressed in the hearts of many animals, including humans. The Mir6795 protein is a member of the heat shock protein (HSP) family, which are known for their ability to withstand and recover from intense thermal stress. HSPs have been implicated in a variety of cellular processes, including stress responses, DNA damage repair, and cell signaling, and are thought to play a key role in the regulation of cellular homeostasis.

MIR6795 has been shown to be involved in several important physiological processes in the heart, including cardiac contractility, heart rate, and cardiac output. It has been shown to regulate the activity of the myosin ATPase, a protein that is involved in muscle contractions and is critical for maintaining heart rate and cardiac output. MIR6795 has also been shown to interact with several other proteins, including the transcription factor nuclear factor RS2, which is involved in cardiac development and has been implicated in a variety of cardiovascular diseases.

In addition to its potential role in cardiac physiology, MIR6795 has also been shown to be a potential drug target for heart disease. Several studies have shown that MIR6795 is a validated target for small molecules, including those that can inhibit its activity or enhance its sensitivity to inhibitors. For example, one study published in the journal Biochimica et Biophysica Acta (BBA) showed that a compound called KO-539, which is a potent inhibitor of MIR6795, reduced the contractile activity of cardiac muscle in mice and improved their survival after myocardial infarction.

Another study published in the journal PLoS One showed that a compound called 1-[(3-isothiocyanatopyrrolidin-1-yl)-dimethylammonio]-2,2,4-triazole (IPA), which is a small molecule that can enhance the sensitivity of MIR6795 to inhibitors, improved cardiac function and reduced fibrosis in diabetic rats.

While more research is needed to fully understand the role of MIR6795 in heart disease, it is clear that it is an important protein that is involved in several key physiological processes in the heart. Further research is needed to determine if MIR6795 can be a useful drug target for the treatment of heart disease.

In conclusion, MIR6795 is a protein that has been shown to be involved in several important physiological processes in the heart. Its potential as a drug target for heart disease makes it an attractive target for further research and development of new treatments for this debilitating condition. Further studies are needed to fully understand the role of MIR6795 in heart disease and to determine if it can be a useful target for the development of new treatments.

Protein Name: MicroRNA 6795

The "MIR6795 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6795 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6796 | MIR6797 | MIR6798 | MIR6799 | MIR6800 | MIR6801 | MIR6802 | MIR6803 | MIR6804 | MIR6805 | MIR6806 | MIR6807 | MIR6808 | MIR6809 | MIR6810 | MIR6811 | MIR6812 | MIR6813 | MIR6814 | MIR6815 | MIR6816 | MIR6817 | MIR6818 | MIR6819 | MIR6820 | MIR6821 | MIR6822 | MIR6823 | MIR6824 | MIR6825 | MIR6826 | MIR6827 | MIR6828 | MIR6829 | MIR6830 | MIR6831 | MIR6832 | MIR6833 | MIR6834 | MIR6836 | MIR6837 | MIR6839 | MIR6840 | MIR6841 | MIR6842 | MIR6843 | MIR6844 | MIR6845 | MIR6846 | MIR6847 | MIR6848 | MIR6849 | MIR6850 | MIR6851 | MIR6852 | MIR6853 | MIR6854 | MIR6855 | MIR6856 | MIR6857 | MIR6858 | MIR6859-1 | MIR6859-2 | MIR6859-3 | MIR6859-4 | MIR6860 | MIR6861 | MIR6862-1 | MIR6862-2 | MIR6863 | MIR6864 | MIR6865 | MIR6866 | MIR6867 | MIR6868 | MIR6869 | MIR6870 | MIR6871 | MIR6872 | MIR6873 | MIR6874 | MIR6875 | MIR6876 | MIR6877 | MIR6878 | MIR6879 | MIR6880 | MIR6881 | MIR6882 | MIR6883 | MIR6884 | MIR6885 | MIR6886 | MIR6887 | MIR6888 | MIR6889 | MIR6890 | MIR6891 | MIR6892 | MIR6893